Inhibikase Therapeutics, Inc.IKTNASDAQ

Revenue (LTM)

-100.0% YoY

Net Income (LTM)

$-28M

-44.6% YoY

Free Cash Flow

$-19M

Revenue CAGR (5Y)

—

Marginsdeclining

FCF($0.0B)

Unprofitable

Metric	Dec 20	Dec 21	Dec 22	Dec 23	Dec 24
Revenue	1	3↑343.9%	0↓96.0%	0↑111.0%	0
Gross Profit	-0	-8↓4127.9%	0↑101.4%	-13↓11544.6%	-0↑99.8%
Operating Income	-3	-15↓423.9%	-18↓22.8%	-20↓10.8%	-29↓42.3%
Net Income	-3	-15↓419.2%	-18↓22.1%	-19↓5.4%	-28↓44.6%
EBITDA	0	0	-18	-20↓10.3%	-27↓38.1%
EPS Diluted	-1.72	-4.88↓183.7%	-4.26↑12.7%	-3.57↑16.2%	-1.16↑67.5%

Metric	Dec 20	Dec 21	Dec 22	Dec 23	Dec 24
Cash & Equivalents	14	41↑192.0%	7↓82.4%	9↑27.5%	56↑516.4%
Total Current Assets	15	42↑187.3%	24↓42.6%	14↓41.7%	98↑592.8%
Total Assets	15	42↑187.3%	25↓41.3%	15↓41.8%	99↑579.7%
Total Current Liabilities	5	4↓14.1%	4↓8.9%	3↓7.0%	4↑8.6%
Total Liabilities	5	4↓18.9%	4↓3.8%	4↓9.5%	4↑5.8%
Total Equity	10	38↑292.6%	21↓45.2%	11↓47.8%	95↑764.2%
Total Debt	0	0↓22.0%	0↑41.1%	1↑77.1%	0↓82.2%
Net Debt	-14	-41↓197.0%	-7↑83.1%	-9↓25.0%	-56↓559.9%

Metric	Dec 20	Dec 21	Dec 22	Dec 23	Dec 24
Operating Cash Flow	-1	-14↓1165.9%	-17↓21.4%	-18↓4.2%	-19↓5.9%
Capital Expenditure	0	0	-0	-0↑94.1%	0
Free Cash Flow	-1	-14↓1165.9%	-18↓23.1%	-18↓2.9%	-19↓5.8%
Stock-Based Comp	1	2↑167.0%	0↓70.1%	1↑9.2%	8↑1527.6%
Net Change in Cash	14	27↑92.3%	-34↓225.2%	2↑105.9%	47↑2294.3%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance